Levin Capital Strategies, L.P. Allogene Therapeutics, Inc. Transaction History
Levin Capital Strategies, L.P.
- $1.08 Billion
- Q3 2025
A detailed history of Levin Capital Strategies, L.P. transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Levin Capital Strategies, L.P. holds 52,500 shares of ALLO stock, worth $61,950. This represents 0.01% of its overall portfolio holdings.
Number of Shares
52,500Holding current value
$61,950% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ALLO
# of Institutions
169Shares Held
160MCall Options Held
146KPut Options Held
97.1K-
Tpg Gp A, LLC Fort Worth, TX18.7MShares$22.1 Million1.28% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$19.4 Million0.0% of portfolio
-
Capital World Investors Los Angeles, CA11.2MShares$13.2 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR11.1MShares$13 Million3.7% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y910.5MShares$12.4 Million0.5% of portfolio
About Allogene Therapeutics, Inc.
- Ticker ALLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 143,807,008
- Market Cap $170M
- Description
- Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...